Our Vision
A healthier, safer and more sustainable world through nanotechnology.
Our Mission
Develop and commercialize innovative nanotechnologies with partners to build distinct brands that improve people’s lives and create long‑term value for shareholders.
Zentek as a Portfolio company
Zentek is an ISO 13485‑certified intellectual property development and commercialization company that operates as a portfolio of businesses in filtration, biosciences and critical minerals. The company uses expertise in graphene‑based nanomaterials and aptamer technologies, together with strategic partnerships, to turn cutting‑edge science into scalable businesses.
Zentek currently allocates capital and capabilities across three core brands: ZenGUARD™, Triera Biosciences and Albany Graphite, each addressing large, long‑term market opportunities.
How We Work
Our focus is to own and steward intellectual property, provide governance and capital, and support commercialization across our brands.
- Own and protect core IP across graphene‑based coatings, aptamer platforms and high‑purity graphite, including global exclusive licences where applicable.
- Provide centralized regulatory, quality and commercialization expertise, backed by an ISO 13485 quality management system and an industrial‑scale production and coating application facility in Guelph, Ontario.
- Allocate capital among ZenGUARD™, Triera Biosciences and Albany Graphite based on risk‑adjusted return potential, external funding opportunities and portfolio balance.
Zentek’s Brands Target Different but Complementary Markets
- ZenGUARD™ - Zentek’s patented technology platform. Utilizing the revolutionary benefits of the carbon-based nanomaterial graphene, ZenGUARD™ is a technology that can be easily applied to materials to enhance their viral filtration efficiency. This boost in protective efficiency has been demonstrated with ZenGUARD™ Antimicrobial Surgical Masks, which are used in the same way as similar surgical mask products. Zentek aims to do the same with HVAC air filters.
- Triera Biosciences - Zentek’s wholly owned biotech brand, built on an exclusive multivalent aptamer platform developed with McMaster University, targeting rapid therapeutic development for infectious diseases and other high‑need conditions.
- Albany Graphite - High‑purity, igneous‑hosted graphite deposit in Northern Ontario, held through Albany Graphite Corp., with recent five‑nines purity, nuclear suitability and near‑theoretical anode performance results that position it within critical minerals and advanced materials supply chains.
Strategic Priorities
Zentek’s strategy focuses on advancing each brand while managing risk and capital at the portfolio level.
- Scale ZenGUARD™ commercialization by securing regulatory approvals, government validation programs and strategic partners to drive adoption of ZenGUARD™‑enhanced products.
- De‑risk and partner Triera’s aptamer platform through focused infectious‑disease programs, government contracts and collaborations that can lead to co‑development, milestones and royalties.
- Advance Albany Graphite as a strategic critical‑minerals asset by completing technical and nuclear‑suitability work, leveraging grants, and evaluating spin‑out, JV, offtake or royalty options to crystallize value.